Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors, primarily the advancement of Olvi-Vec in a pivotal Phase 3 trial for platinum-resistant or refractory ovarian cancer, with top-line results expected in the second half of 2026. He notes that earlier Phase 2 data in this setting showed markedly stronger response rates and progression-free survival than historical benchmarks, and that regulatory alignment on an interim overall survival analysis could allow for full approval without an additional confirmatory study.
McCarthy also highlights encouraging interim results from systemic, intravenous Olvi-Vec programs in both non-small cell and small cell lung cancer, which provide additional optionality beyond the lead ovarian cancer indication. From a valuation standpoint, he models U.S. commercialization of Olvi-Vec in ovarian cancer in 2027 and in NSCLC in 2029, applies risk-adjusted revenues and a 20% discount rate, and arrives at a $12 twelve-month price target, which implies meaningful upside from current levels and supports maintaining a Buy recommendation.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $31.00 price target.